Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16602936 | 1.00 | MGAM (0.40) | MGAMCA1CA2GAASI | |
| SCHEMBL10100000 | 1.00 | MGAM (0.40) | MGAMCA1CA2GAASI | |
| SCHEMBL10063791 | 1.00 | MGAM (0.40) | MGAMCA1CA2GAASI | |
| SCHEMBL13825709 | 1.00 | MGAM (0.40) | MGAMCA1CA2GAASI | |
| SCHEMBL14403895 | 0.82 | MGAM (0.39) | MGAMCA1CA2GAASI | |
| SCHEMBL14232901 | 0.82 | MGAM (0.39) | MGAMCA1CA2GAASI | |
| SCHEMBL12510719 | 0.82 | MGAM (0.39) | MGAMCA1CA2GAASI | |
| SCHEMBL13300885 | 0.80 | — | — | |
| SCHEMBL13321423 | 0.80 | — | — | |
| SCHEMBL14403629 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| US-20200048183-A1 | ANTIMICROBIAL AGENTS | UNIV WARWICK (GB) | 2020-02-13 | — | — | US | disclosed |
| EP-2949652-B1 | Intermediates for the preparation of halichondrin B | EISAI R&D MAN CO LTD (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-RE46965-E1 | Intermediates for the preparation of analogs of Halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-07-24 | — | — | US | disclosed |
| US-9475752-B2 | Method for manufacturing 3,4,5-tricaffeoylquinic acid | FUJIFILM CORPORATION (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9475752-B2 | Method for manufacturing 3,4,5-tricaffeoylquinic acid | FUJIFILM CORPORATION (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9303050-B2 | Intermediates for the preparation of analogs of Halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20160023986-A1 | METHOD FOR MANUFACTURING 3,4,5-TRICAFFEOYLQUINIC ACID | FUJIFILM CORPORATION (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20160023986-A1 | METHOD FOR MANUFACTURING 3,4,5-TRICAFFEOYLQUINIC ACID | FUJIFILM CORPORATION (JP) | 2016-01-28 | — | — | US | disclosed |
| EP-2949652-A1 | Intermediates for the preparation of halichondrin B | Eisai R&D Management Co., Ltd. (JP) | 2015-12-02 | — | — | EP | disclosed |
| US-20120283331-A1 | Anti-Inflammatory Quinic Acid Derivatives for Radioprotection/Radiomitigation | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-11-08 | — | — | US | disclosed |
| US-8115031-B2 | Anti-inflammatory quinic acid derivatives for oral administration | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2012-02-14 | — | — | US | disclosed |
| US-8115031-B2 | Anti-inflammatory quinic acid derivatives for oral administration | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2012-02-14 | — | — | US | disclosed |
| US-7982060-B2 | Intermediates for the preparation of analogs of Halichondrin B | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-19 | — | — | US | disclosed |
| WO-2010132504-A1 | ANTI-INFLAMMATORY QUINIC ACID DERIVATIVES FOR RADIOPROTECTION/RADIOMITIGATION | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20090234015-A1 | Anti-Inflammatory Quinic Acid Derivatives for Oral Administration | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2009-09-17 | — | — | US | disclosed |
| US-20090234015-A1 | Anti-Inflammatory Quinic Acid Derivatives for Oral Administration | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2009-09-17 | — | — | US | disclosed |
| WO-2009062200-A1 | ANTI-INFLAMMATORY QUINIC ACID DERIVATIVES FOR ORAL ADMINISTRATION | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20070244187-A1 | Intermediates for the Preparation of Halichondrin B | EISAI CO., LTD (JP) | 2007-10-18 | — | — | US | disclosed |
| US-6593314-B1 | Useful in the inhibition of neuraminidase enzymes from disease- causing microorganisms, especially influenza neuraminidase, pharmaceutical formulations containing same, processes and intermediates for preparing said compounds, | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160023986-A1 | METHOD FOR MANUFACTURING 3,4,5-TRICAFFEOYLQUINIC ACID | HAAO, CUL5, ACMSD | MGAM 1088/4885CA1 3855/4885CA2 3279/4885 |
| US-20090234015-A1 | Anti-Inflammatory Quinic Acid Derivatives for Oral Administration | NFKBIA, NFRKB, IKBKB | MGAM 1927/4885CA1 2232/4885CA2 2313/4885 |
| US-20070244187-A1 | Intermediates for the Preparation of Halichondrin B | CDK4, CCNB1, CDK14 | MGAM 4853/4885CA1 3967/4885CA2 3356/4885 |
| US-20200048183-A1 | ANTIMICROBIAL AGENTS | C3AR1, HCAR3, C5AR1 | MGAM 4097/4885CA1 1543/4885CA2 907/4885 |
| US-20120283331-A1 | Anti-Inflammatory Quinic Acid Derivatives for Radioprotection/Radiomitigation | NQO2, SQSTM1, CTSA | MGAM 1796/4885CA1 2228/4885CA2 3340/4885 |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | MGAM 193/4885CA1 95/4885CA2 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.